Clinical Study
A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
Table 4
The results of group and subgroup analyses according to the comparison of mean WHAQ scores changes between groups.
| | |
Between groups | ANCOVA model | | | | | | |
Premenstrual |
Menstrual |
Postmenstrual | Mean WHAQ scores | | DSG | DRSP | Sig | DSG | DRSP | Sig | DSG | DRSP | Sig |
| | Baseline | 19.49 ± 6.76 | 21.33 ± 8.53 |
0.259 | 17.13 ± 5.88 | 17.42 ± 6.41 | 0.824 | 5.84 ± 1.98 | 6.16 ± 2.88 | 0.552 | Total | 3rd cycle | 19.07 ± 6.27 | 14.78 ± 6.28 | 0.000 | 17.82 ± 6.11 | 12.98 ± 4.27 | 0.000 | 5.96 ± 2.04 | 4.80 ± 1.50 | 0.000 | | 6th cycle | 16.24 ± 6.48 | 7.62 ± 2.46 | 0.000 | 15.40 ± 5.42 | 7.49 ± 2.87 | 0.000 | 5.38 ± 1.54 | 4.29 ± 0.82 | 0.000 | | Baseline | 7.76 ± 3.21 | 7.38 ± 3.77 | 0.610 | 7.16 ± 3.02 | 5.93 ± 3.20 | 0.066 | 1.51 ± 1.36 | 1.38 ± 1.48 | 0.657 | Negative effect | 3rd cycle | 7.33 ± 2.95 | 5.07 ± 3.13 | 0.000 | 7.11 ± 2.99 | 4.36 ± 2.68 | 0.000 | 1.47 ± 1.38 | 0.80 ± 1.14 | 0.006 | | 6th cycle | 5.60 ± 3.10 | 1.56 ± 1.52 | 0.000 | 5.67 ± 2.99 | 1.58 ± 1.34 | 0.000 | 1.13 ± 1.27 | 0.07 ± 0.33 | 0.000 | | Baseline | 4.71 ± 3.08 | 5.51 ± 3.61 | 0.261 | 2.87 ± 2.74 | 3.62 ± 2.90 | 0.208 | 0.36 ± 0.80 | 0.69 ± 1.18 | 0.121 | Water retention | 3rd cycle | 4.51 ± 2.98 | 3.64 ± 2.39 | 0.000 | 3.51 ± 2.67 | 2.42 ± 1.83 | 0.000 | 0.56 ± 0.94 | 0.29 ± 0.66 | 0.005 | | 6th cycle | 3.87 ± 2.37 | 1.98 ± 1.82 | 0.000 | 3.22 ± 2.32 | 1.33 ± 1.43 | 0.000 | 0.38 ± 0.61 | 0.16 ± 0.56 | 0.043 | | Baseline | 4.49 ± 3.29 | 5.84 ± 4.31 | 0.097 | 4.56 ± 3.17 | 5.27 ± 3.60 | 0.322 | 0.73 ± 0.96 | 0.87 ± 1.12 | 0.546 | Impaired concentration | 3rd cycle | 4.11 ± 3.41 | 3.27 ± 3.11 | 0.000 | 3.96 ± 2.90 | 3.02 ± 2.34 | 0.000 | 0.62 ± 0.94 | 0.36 ± 0.68 | 0.063 | | 6th cycle | 3.27 ± 3.14 | 0.93 ± 1.10 | 0.000 | 3.20 ± 2.70 | 1.11 ± 1.49 | 0.000 | 0.38 ± 0.86 | 0.04 ± 0.30 | 0.013 | | Baseline | 1.84 ± 1.63 | 2.09 ± 1.47 | 0.457 | 1.53 ± 1.34 | 1.80 ± 1.29 | 0.339 | 0.18 ± 0.54 | 0.27 ± 0.58 | 0.452 | Increased appetite | 3rd cycle | 1.96 ± 1.36 | 1.33 ± 1.07 | 0.000 | 1.58 ± 1.20 | 1.11 ± 0.96 | 0.000 | 0.36 ± 0.57 | 0.11 ± 0.32 | 0.007 | | 6th cycle | 2.04 ± 1.28 | 1.07 ± 1.03 | 0.000 | 1.38 ± 1.15 | 0.62 ± 0.86 | 0.000 | 0.24 ± 0.48 | 0.11 ± 0.38 | 0.167 | | Baseline | 0.64 ± 0.83 | 0.51 ± 0.63 | 0.392 | 1.04 ± 0.85 | 0.80 ± 0.79 | 0.161 | 3.02 ± 0.66 | 2.96 ± 0.64 | 0.626 | Feeling of well being | 3rd cycle | 1.11 ± 0.91 | 1.47 ± 0.73 | 0.008 | 1.62 ± 0.75 | 2.07 ± 1.01 | 0.002 | 2.91 ± 0.76 | 3.24 ± 0.86 | 0.042 | | 6th cycle | 1.42 ± 0.81 | 2.09 ± 0.67 | 0.000 | 1.89 ± 0.83 | 2.78 ± 0.67 | 0.000 | 3.20 ± 0.76 | 3.91 ± 0.29 | 0.000 | | Baseline | 0.04 ± 0.30 | 0.00 ± 0.00 | 0.320 | 0.04 ± 0.30 | 0.00 ± 0.00 | 0.320 | 0.04 ± 0.30 | 0.00 ± 0.00 | 0.320 | Undesirable hair changes | 3rd cycle | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 | | 6th cycle | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 | 0.04 ± 0.30 | 0.00 ± 0.00 | 1.000 |
|
|
DSG: desogestrel and DRSP: drospirenone.
|